Why Is Mesoblast Stock Trading Higher On Monday?

Monday, Mesoblast Limited MESO announced that the FDA supports an accelerated approval pathway for rexlemestrocel-L, its allogeneic mesenchymal precursor cell product, for end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD). In the…#mesoblastlimited #fda #lvadmpcstudy #lvad #stro3 #weans #mesoblast #lvads #meso
Source: Reuters: Health - Category: Consumer Health News Source Type: news